Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.
WAYNE, Pa. - Palvella Therapeutics Inc. (NASDAQ:PVLA), whose stock has gained nearly 19% year-to-date and currently trades at $14.25, announced today that results from its Phase 2... ByInvesting ...
As of 8:07:23 a.m. GMT+1. Market Open.
Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from ...
This data feed is not available at this time.
ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...
Dyne Therapeutics Inc. 4.43% $1.38B ...
Sanofi S.A. Part Cert-1.97% €8.03M ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback